Commercializing Medical IT and Health Management Services
First written in FY2016. 12 of 25 entries say "Advanced", first in FY2017. Latest entry: 2026-07-30.
0 other companies' latest entry also says "Cited as achieved".
- 2026-07-30Cited as achievedEarnings
「In the solutions business, net sales increased 18.9% year on year to ¥4,068 million, reflecting higher sales in medical and healthcare solutions, increased demand for enhanced security among public-sector organizations and other customers, and the acquisition of new customers for shareholder benefit services. Operating profit recovered year on year, but the business posted an operating loss of ¥72 million due mainly to higher selling, general and administrative expenses associated with strengthening the sales structure for medical and healthcare solutions.」
The company reports higher sales and a recovery in operating profit in medical and healthcare solutions, while the solutions business continues to post an operating loss. - FY2026AdvancedAnnual report
「In the solutions business, special demand related to the government's promotion of medical DX in medical and healthcare solutions, growing demand for stronger security among public-sector organizations and other entities, and the acquisition of major customers for shareholder benefit services helped revenue increase 15.0% from the previous consolidated fiscal year to ¥17,720 million. Operating profit was ¥1,488 million, approximately double the previous consolidated fiscal year.」
For the solutions business, which had reported lower profit and declining profit margins through the previous fiscal year, revenue reached ¥17,720 million and operating profit ¥1,488 million, driven by demand related to medical DX in the medical and healthcare businesses. Operating profit recovered to approximately twice the previous fiscal year's level. - 2026-05-08AdvancedManagement plan
「Solutions business Net sales (Note) ¥17.7 billion → ¥23.0 billion」
For the solutions business, the company specified a policy of improving business scale and profit margins as its second core business and presented a net sales target. - FY2026-H1Continued decline in solutions business profitAnnual report
「In the solutions business, orders for security and shareholder benefit services remained strong and revenue increased, but revenue declined in the medical, healthcare and RFID businesses. As a result, revenue increased 4.6% year on year to ¥7,969 million, while operating profit decreased by ¥72 million to ¥149 million.」
Revenue increased due to higher orders for security and shareholder benefit services, while operating profit decreased ¥72 million year on year to ¥149 million due to lower revenue in the medical, healthcare and RFID businesses. The filing describes the continued decline in solutions business profitability from the previous fiscal year. - FY2025Declining profit margins in the solutions businessAnnual report
「In the solutions business, revenue increased 5.9% from the previous fiscal year to ¥15,411 million, due to higher orders for security products, RFID-related solutions, shareholder benefit services and other offerings. Operating profit, however, decreased by ¥98 million to ¥772 million due in part to lower profit margins on certain solutions.」
Revenue increased due to higher orders for security, RFID and shareholder benefit services, while operating profit decreased by ¥98 million due to lower profit margins on certain solutions. - FY2025-H1Declining profitability in the solutions businessAnnual report
「In the solutions business, orders for existing solutions, including security and shareholder benefit services, increased. However, revenue from medical and healthcare solutions was limited to a 3.0% year-on-year increase, or ¥7,620 million, due in part to a decline following the special demand recorded in the same period of the previous year. Operating profit decreased by ¥326 million to ¥222 million, due to higher selling, general and administrative expenses at subsidiaries and the recognition of PMI-related costs.」
Business revenue increased 3.0% year on year due to higher orders for existing solutions, while operating profit decreased by ¥326 million from the same period of the previous year due to the decline following special demand in the medical and healthcare businesses and PMI-related costs. - FY2024AdvancedAnnual report
「In the solutions business, new solutions from M&A in the medical, healthcare and RFID fields made a significant contribution to business expansion, while existing solutions also expanded. As a result, revenue increased 99.3% from the previous fiscal year to ¥14,555 million.」
The expansion of new solutions from M&A in the medical, healthcare and RFID fields, together with the expansion of existing solutions, resulted in full-year solutions business revenue of ¥14,555 million, up 99.3% from the previous fiscal year. - FY2024-Q3AdvancedAnnual report
「In the solutions business, new solutions from M&A in the medical, healthcare and RFID fields made a significant contribution to business expansion, while existing solutions also expanded. As a result, revenue increased 91.1% year on year to ¥10,883 million. Operating profit increased 27.9% to ¥668 million, despite higher amortization of goodwill and other costs associated with M&A.」
The filing states that the expansion of new solutions from M&A, including in the medical and healthcare fields, together with the expansion of existing solutions, resulted in concrete progress, with solutions business revenue reaching ¥10,883 million, up 91.1% year on year. - FY2024-Q2AdvancedAnnual report
「In May, with the aim of strengthening the solutions business, the company made 株式会社ノーザ, which has strengths in the dental systems business, a subsidiary and expanded its range of medical solutions, including claims-processing computer systems for dental practices and dialysis workflow support systems.」
In addition to expanding the medical product lineup through the acquisition of ノーザ, new solutions from M&A in the medical, healthcare and RFID fields contributed to business expansion. Solutions business revenue increased 90.7% year on year to ¥7,595 million, and operating profit increased 91.9% to ¥612 million. - FY2024-Q1AdvancedAnnual report
「On 9 May 2023, the company acquired shares in 株式会社ノーザ and made it a subsidiary. By making 株式会社ノーザ a consolidated subsidiary and newly providing services in the medical field, primarily for the dental industry, the company aims to expand the scope and scale of the Group's solutions business.」
The company made ノーザ a subsidiary with a 91.6% voting-rights ratio and began providing medical solutions, including dental claims-processing computer systems and dialysis workflow support systems. - FY2023AdvancedAnnual report
「On 9 May 2023, the company acquired shares in 株式会社ノーザ and made it a subsidiary. By making 株式会社ノーザ a consolidated subsidiary and newly providing services in the medical field, primarily for the dental industry, the company aims to expand the scope and scale of the Group's solutions business.」
By making 株式会社ノーザ, which provides dental claims-processing computers and other products, a subsidiary with a 91.6% voting-rights ratio, the company is giving concrete form to the expansion of its solutions business in the medical and healthcare fields. - FY2021RestatedAnnual report
「As demand rapidly increased in various fields for solutions supporting remote activities due to the impact of the COVID-19 pandemic, the company worked to further promote the CAReNA remote health support service and the ManaBOX school e-portfolio system, while creating and developing new solutions that meet customer needs and focusing on making the solutions business the Group's second pillar.」
The company reconfirmed its policy of continuing to promote and develop CAReNA, ManaBOX and new remote support solutions, and making the solutions business its second pillar. - FY2021-Q3RestatedAnnual report
「Amid rapidly growing demand for solutions that support remote activities in various fields, not only ordinary corporate activities, due to the impact of the COVID-19 pandemic, the company worked to further promote the CAReNA remote health support service and the ManaBOX school e-portfolio system, while focusing on creating and developing new solutions using new technologies.」
The company continues to promote CAReNA and ManaBOX and to create and develop solutions using new technologies. No specific milestones, such as new implementation numbers or market launches, have been presented. - FY2021-Q2RestatedAnnual report
「The company worked to further promote the remote health support service CAReNA and the school e-portfolio system ManaBOX, while focusing on creating and developing new solutions using new technologies.」
The company continues to promote and develop solutions, including the CAReNA remote health support service. No specific milestones, such as new implementation numbers or market launches, have been specified. - FY2020AdvancedAnnual report
「The company is also focusing on expanding solutions for preventing chronic diseases such as diabetes and hypertension overseas, including in China.」
The company explicitly stated its policy of expanding chronic disease prevention solutions overseas, particularly in China. - FY2020-Q3RestatedAnnual report
「With the healthcare business having entered the expansion-sales phase from the research and development phase, the company integrated in April the healthcare business operated by the Business Development Headquarters and the Overseas Business Headquarters, and strengthened its operating structure as the Healthcare Business Division.」
The company reconfirmed the healthcare business's transition to the expansion-sales phase and the strengthening of its operating structure through the integration of businesses operated in Japan and overseas. No new specific milestones were presented. - FY2020-Q2RestatedAnnual report
「With the healthcare business having entered the expansion-sales phase from the research and development phase, the company changed the name of the Business Development Headquarters to the Healthcare Business Division in April, integrated the healthcare business previously operated by the Overseas Business Headquarters, and strengthened its operating structure.」
The company reconfirmed the healthcare business's transition from the research and development phase to the expansion-sales phase and the strengthening of its operating structure through the integration of the overseas business. No new milestones from the previous quarter were presented. - FY2020-Q1AdvancedAnnual report
「With the healthcare business having entered the expansion-sales phase from the research and development phase, the company changed the name of the Business Development Headquarters to the Healthcare Business Division, integrated the healthcare business previously operated by the Overseas Business Headquarters, and strengthened its operating structure.」
As the healthcare business moved from the research and development stage to the expansion-sales stage, the company changed the organizational name, integrated the overseas business, and strengthened its operating structure. - FY2019AdvancedAnnual report
「The company conducted the following research and development for commercial sale: (1) Functional enhancements to remote health support services that contribute to preventing lifestyle-related diseases; functional enhancements to the corporate health management support service (features for users of specified health guidance) and functional enhancements to the corporate health management support service (nutrition data integration); functional enhancements for overseas markets (nutrition guidance features for China); functional enhancements for overseas medical institutions (features for nursing facilities in Thailand); and (2) development of a service that visualizes blood glucose trends and contributes to diabetes prevention and lifestyle improvement.」
For the remote health support service, the company developed features for specified health guidance, nutrition data integration, China and medical institutions in Thailand, and has also begun developing a new service that visualizes blood glucose trends. - FY2018AdvancedAnnual report
「Market launches have been carried out for (1), (2) and (4). (1) Development to expand the functions of remote health support services that contribute to preventing lifestyle-related diseases • Expansion of the corporate health management support service (stress checks using brain activity measurement) Expansion of the corporate health management support service (introduction of health points and exercise content) • Customization for overseas markets and functional enhancements for overseas medical institutions (2) Development of regional healthcare coordination services that contribute to resolving healthcare challenges in a super-aging society」
The company is advancing functional enhancements to its remote health support service, including stress checks using brain activity measurement, health points, and enhancements for overseas markets and overseas medical institutions, while continuing market launches. The regional healthcare coordination service is also listed as a development target. - FY2018-Q3RestatedAnnual report
「Against this backdrop, as the Group entered the final year of its three-year Medium-Term Management Plan, it continued proactive order acquisition and strengthened and advanced its service-based business initiatives, including the rollout of proprietary products in healthcare IT and education IT and entry into new services through M&A, in order to achieve the targets set out in the plan.」
The company continues to roll out its own products in healthcare IT and education IT. No specific new healthcare IT milestones, such as market launches or implementations, have been specified. - FY2018-Q2RestatedAnnual report
「Against this backdrop, as the Group entered the final year of its three-year Medium-Term Management Plan, it continued proactive order acquisition and strengthened and advanced its service-based business initiatives, including the rollout of proprietary products in healthcare IT and education IT, in order to achieve the targets set out in the plan.」
The company continues to strengthen its service-based business, including the rollout of its own products in healthcare IT and education IT. No new healthcare IT progress, such as a market launch or implementation, has been specified. - FY2018-Q1RestatedAnnual report
「Against this backdrop, as the Group entered the final year of its three-year Medium-Term Management Plan, it continued proactive order acquisition and strengthened and advanced its service-based business initiatives, including the rollout of proprietary products in healthcare IT and education IT, in order to achieve the targets set out in the plan.」
The company continues to strengthen its service-based business, including the rollout of its own products in healthcare IT. The filing does not specify any new healthcare IT progress, such as a market launch or implementation. - FY2017AdvancedAnnual report
「(1) Development of remote health support services that contribute to preventing lifestyle-related diseases (2) Development of a dementia-prevention system, including brain training, in response to China's elderly-care policies (3) Development of regional healthcare coordination services that contribute to resolving healthcare challenges in a super-aging society (4) Development of a telehealth system for remotely monitoring patients receiving care at home (5) Development of a medical safety monitoring system that supports stronger medical safety management (6) Development of health support tools that assist family pharmacists in providing health support to local residents」
The remote health support service and China's dementia-prevention system have been launched, the regional healthcare coordination service has been introduced ahead of schedule at selected medical institutions, and the telehealth and medical safety monitoring systems have advanced to trial operation, according to the filing. - FY2016First statedAnnual report
「(6) Development of regional healthcare coordination services that contribute to resolving healthcare challenges in a super-aging society (7) Development of a telehealth system for remotely monitoring patients receiving care at home (8) Development of wellness programs that contribute to preventing lifestyle-related diseases (9) Development of health support tools that assist family pharmacists in providing health support to local residents」
Healthcare IT is positioned as one of the pillars of the non-contract development business, with regional healthcare coordination, telehealth, wellness and health support identified as development targets.